Clinical Trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Study acronym: EMBARK
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Protocol Amendment History 1 change
notable Trial sites expanded: 298 -> 301 locations 2026-05-08
Trial Details
NCT Number NCT06883305
Lead Sponsor AstraZeneca
Collaborators: Amgen
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 990 participants
Start Date 2025-03-18
Primary Completion 2029-03-13 (estimated)
Study Completion 2029-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-24